Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2010-05-27
2010-11-23
Nashed, Nashaat T (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C514S002600, C536S023400, C536S023700
Reexamination Certificate
active
07838266
ABSTRACT:
Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.
REFERENCES:
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5777078 (1998-07-01), Bayley et al.
patent: 5798218 (1998-08-01), Buckley
patent: 5817771 (1998-10-01), Bayley et al.
patent: 5824776 (1998-10-01), Bayley et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5866679 (1999-02-01), DeFeo-Jones et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5985877 (1999-11-01), Dionne et al.
patent: 5998362 (1999-12-01), Feng et al.
patent: 6143864 (2000-11-01), DeFeo-Jones et al.
patent: 6180356 (2001-01-01), London et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 6265540 (2001-07-01), Isaacs et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6368598 (2002-04-01), D'Amico et al.
patent: 6391305 (2002-05-01), Feng et al.
patent: 6410514 (2002-06-01), Isaacs et al.
patent: 6495315 (2002-12-01), Hildreth et al.
patent: 6504014 (2003-01-01), Isaacs et al.
patent: 6545131 (2003-04-01), Isaacs et al.
patent: 6593095 (2003-07-01), Buckley et al.
patent: 7053042 (2006-05-01), Denmeade et al.
patent: 7094750 (2006-08-01), Yu et al.
patent: 7456146 (2008-11-01), Yu et al.
patent: 2002/0041880 (2002-04-01), DeFeo-Jones et al.
patent: 2002/0045736 (2002-04-01), Yu et al.
patent: 2002/0077454 (2002-06-01), Yu et al.
patent: 2005/0266512 (2005-12-01), Buckley
patent: 1 052 287 (2000-11-01), None
patent: 1 052 288 (2000-11-01), None
patent: WO 94/25616 (1994-11-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/20688 (1996-07-01), None
patent: WO 97/40857 (1997-11-01), None
patent: WO 98/11211 (1998-03-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52966 (1998-11-01), None
patent: WO 99/02175 (1999-01-01), None
patent: WO 99/20252 (1999-04-01), None
patent: WO 00/01419 (2000-01-01), None
patent: WO 01/09165 (2001-02-01), None
patent: WO 01/85777 (2001-11-01), None
patent: WO 02/26777 (2002-04-01), None
patent: WO 02/38799 (2002-05-01), None
patent: WO 02/43773 (2002-06-01), None
Walker, B., and Bayley, H., 1994, “A pore-forming protein with a protease-activated trigger”, Protein Engineering, vol. 7, No. 1, pp. 91-97.
Abrami et al., “The Pore-Forming Toxin Proaerolysin is Activated by Furin,”J. Biol. Chem. 273:32656-32661 (1998).
Audtho et al., “Production of Chymotrypsin-ResistantBacillus thuringiensisCry2Aa1 δ-Endotoxin by Protein Engineering,”Appl. Environ. Micriobiol. 65:4601-4605 (1999).
Ballard et al., “The Primary Structure ofClostridium septicumAlpha-Toxin Exhibits Similarity with That ofAeromonas hydrophilaAerolysin,”Infect. Immun. 63:340-344 (1995).
Barry et al., “The Channel-Forming Protein Proaerolysin Remains a Dimer at Low Concentrations in Solution,”J. Biol. Chem. 276:551-554, 2001.
Chen et al., “Glycophosphatidylinositol-Anchored Protein Deficiency as a Marker ofMutatorPhenotypes in Cancer,”Cancer Res. 61:654-658 (2001).
Correale et al., “Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide,”J. Immunol. 161:3186-3194 (1998).
Denmeade et al., “Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-Specific Antigen,”Cancer Res. 57:4924-4930 (1997).
Gong et al., “Overview of Evolving Strategies Incorporating Prostate-Specific Membrane Antigen as Target for Therapy,”Mol. Urol. 4:217-222 (2000).
Gordon et al., “Clostridium septicumAlpha-Toxin Is Proteolytically Activated by Furin,”Infect. Immun. 65:4130-4134 (1997).
MacKenzie et al., “Analysis of Receptor Binding by the Channel-Forming Toxin Aerolysin Using Surface Plasmon Resonance,”J. Biol. Chem. 274:22604-22609 (1999).
Pang et al., “Activation and Fragmentation ofBacillus thuringiensisδ-Endotoxin by High Concentrations of Proteolytic Enzymes,”Can. J. Microbiol. 45:816-825 (1999).
Rosen et al. “Enzymatic Activation of a Modified Proaerolysin Toxin by Prostate-Specific Antigen (PSA) as Treatment for Prostate Cancer,”Proceedings of the American Association for Cancer Research Annual Meeting43:92 (2002).
Rossjohn et al., “Aerolysin and Pertussis Toxin Share a Common Receptor-Binding Domain,”EMBO J.16:3426-3434 (1997).
Spyres et al., “Cytosolic Delivery and Characterization of the TcdB Glucosylating Domain by Using a Heterologous Protein Fusion,”Infection Immun. 69:599-601 (2001).
Tanha et al., “Optimal Design Features of Camelized Human Single-Domain Antibody Libraries,”J. Biol. Chem.276:24774-24780 (2001).
Walker and Bayley, “A Pore-Forming Protein with a Protease-Activated Trigger,”Protein Eng.7:91-97 (1994).
Williams et al., “Tumoricidal Effects of a PSA-Activated Pore-Forming Toxin,”Proceedings of the American Association for Cancer Research46:1446 (2005).
Chen et al:. “Glycophosphatidylinositol-Anchored Protein Deficiency as a Marker ofMutatorPhenotypes in Cancer,”Cancer Res.61:654-658 (2001).
Correale et al., “Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide,”J. Immunol.161:3186-3194 (1998).
Buckley J. Thomas
Denmeade Samuel R.
Isaacs John T.
Klarquist & Sparkman, LLP
Moore William W
Nashed Nashaat T
The Johns Hopkins University
University of Victoria Innovation and Development Corporation
LandOfFree
Proaerolysin containing protease activation sequences and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proaerolysin containing protease activation sequences and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proaerolysin containing protease activation sequences and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251826